VPL vs XBI
Vanguard FTSE Pacific ETF vs SPDR S&P Biotech ETF
- • VPL has the lower expense ratio at 0.07% vs 0.35% for XBI.
- • VPL pays a higher dividend yield (2.61%).
Side-by-side metrics
| Metric | VPL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.07% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.61% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $13.83B | $10.73B |
YTD return | 24.00% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.10 | 1.10 |
P/E ratio | 18.31 | — |
Last price | $113.07 | $164.28 |
Inception | — | — |
Issuer | Vanguard | State Street |
VPL top holdings
| 005930.KS | Samsung Electronics Co Ltd | 7.64% |
| 000660.KS | SK Hynix Inc | 6.51% |
| BHP.AX | BHP Group Ltd | 1.69% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 1.60% |
| 7203.T | Toyota Motor Corp | 1.55% |
| CBA.AX | Commonwealth Bank of Australia | 1.53% |
| 9984.T | SoftBank Group Corp | 1.42% |
| 8035.T | Tokyo Electron Ltd | 1.15% |
| 6501.T | Hitachi Ltd | 1.08% |
| 8316.T | Sumitomo Mitsui Financial Group Inc | 1.03% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VPL
VPL (Vanguard FTSE Pacific ETF) is Developed Pacific-region equities. Managed by Vanguard, the fund carries $13.8B in assets under management, an expense ratio of 0.07%, a dividend yield of 2.61%. Its largest holding is Samsung Electronics Co Ltd (005930.KS), which represents 7.6% of the portfolio. Real Estate is the fund's largest sector exposure at 3.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.